Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms

Jahangir Abdi; Guoan Chen; Hong Chang

doi:10.18632/oncotarget.1497

journal article Nov 24, 2013

Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms

Jahangir Abdi Guoan Chen

Hong Chang

Oncotarget Vol. 4 No. 12 pp. 2186-2207 · Impact Journals, LLC

View at Publisher Save 10.18632/oncotarget.1497

Topics

No keywords indexed for this article. Browse by subject →

References

253

[1]

Carrasco "Pathogenesis of myeloma" Annu Rev Pathol (2011) 10.1146/annurev-pathol-011110-130249

[2]

Rajkumar "Monoclonal gammopathy of undetermined significance" Br J Haematol (2006) 10.1111/j.1365-2141.2006.06235.x

[3]

Dewald "Genomic abnormalities in monoclonal gammopathy of undetermined significance" Blood (2002) 10.1182/blood.v100.4.1417.h81602001417_1417_1424

[4]

Walker "The molecular classification of multiple myeloma" Blood (2006) 10.1182/blood-2005-11-013458

[5]

Matsui "Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis" Anticancer Agents Med Chem (2010) 10.2174/187152010790909344

[6]

Ullah "Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy" Asian Pac J Cancer Prev (2008)

[7]

Gottesman "Mechanisms of cancer drug resistance" Annu Rev Med (2002) 10.1146/annurev.med.53.082901.103929

[8]

Sonneveld "Multidrug resistance in haematological malignancies" J Intern Med (2000) 10.1046/j.1365-2796.2000.t01-1-00689.x

[9]

Janne "Circumventing cancer drug resistance in the era of personalized medicine" Cancer Discov (2012) 10.1158/2159-8290.cd-12-0012

[10]

Swanton "Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference" Eur J Cancer (2010) 10.1016/j.ejca.2010.03.019

[11]

Raaijmakers "ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia" Leukemia (2007) 10.1038/sj.leu.2404859

[12]

Marie "Drug resistance in hematologic malignancies" Curr Opin Oncol (2001) 10.1097/00001622-200111000-00008

[13]

Cabot "Ceramide glycosylation potentiates cellular multidrug resistance" FASEB J (2001) 10.1096/fj.00-0223com

[14]

Bendall "Oncogenic properties of sphingosine kinases in haematological malignancies" Br J Haematol (2013) 10.1111/bjh.12302

[15]

Ghidoni "Sphingolipid players in the leukemia arena" Biochim Biophys Acta (2006) 10.1016/j.bbamem.2006.06.016

[16]

Xiong "Expression of ABCB5 gene in hematological malignances and its significance" Leuk Lymphoma (2012) 10.3109/10428194.2011.637214

[17]

June "NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science" Biol Blood Marrow Transplant (2010) 10.1016/j.bbmt.2010.03.002

[18]

Wang "The resistance mechanisms of proteasome inhibitor bortezomib" Biomarker Research (2013)

[19]

Morgan "A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value" Blood (2010) 10.1182/blood-2010-04-279596

[20]

Munshi "Dysfunctional homologous recombination mediates genomic instability and progression in myeloma" Blood (2009) 10.1182/blood-2007-05-089193

[21]

Chen-Kiang "International Myeloma Working Group molecular classification of multiple myeloma: spotlight review" Leukemia (2009) 10.1038/leu.2009.174

[22]

Davies "Understanding the molecular biology of myeloma and its therapeutic implications" Expert Rev Hematol (2012) 10.1586/ehm.12.51

[23]

Crowley "Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells" Blood (2002) 10.1182/blood.v99.5.1745

[24]

Spencer "The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies" Blood Cancer J (2012) 10.1038/bcj.2012.37

[25]

Pilarski "In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression" Blood (2003) 10.1182/blood-2002-06-1675

[26]

Stewart "Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance" J Clin Oncol (2005) 10.1200/jco.2005.17.129

[27]

Greipp "Clinical and biologic implications of recurrent genomic aberrations in myeloma" Blood (2003) 10.1182/blood-2002-10-3017

[28]

Fonseca "Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy" Blood (2005) 10.1182/blood-2005-04-1411

[29]

Keith Stewart "The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant" Br J Haematol (2004) 10.1111/j.1365-2141.2004.04867.x

[30]

Anderson "Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma" N Engl J Med (2008) 10.1056/nejmoa0801479

[31]

Hulin "Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)" J Clin Oncol (2010) 10.1200/jco.2010.28.3945

[32]

Reece "Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma" Leuk Res (2007) 10.1016/j.leukres.2006.08.002

[33]

Reece "Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains" Leuk Res (2011) 10.1016/j.leukres.2010.05.002

[34]

Bahlis "Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13" Blood (2009) 10.1182/blood-2008-12-193458

[35]

Bataille "Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors" Blood (2001) 10.1182/blood.v98.10.3082

[36]

Kuehl "Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma" Proc Natl Acad Sci U S A (2000) 10.1073/pnas.97.1.228

[37]

Fonseca "Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma" Leukemia (2011) 10.1038/leu.2011.53

[38]

Huber "Expression of the c-myc proto-oncogene in multiple myeloma and chronic lymphocytic leukemia: an in situ analysis" Blood (1991) 10.1182/blood.v78.1.180.180

[39]

Ameglio "c-MYC deregulation is involved in melphalan resistance of multiple myeloma: role of PDGF-BB" Int J Immunopathol Pharmacol (2006)

[40]

Richardson "Treatment options for relapsed and refractory multiple myeloma" Clin Cancer Res (2011) 10.1158/1078-0432.ccr-10-1805

[41]

Greipp "Clinical course of patients with relapsed multiple myeloma" Mayo Clin Proc (2004) 10.4065/79.7.867

[42]

Spencer "MEK inhibitors as a chemotherapeutic intervention in multiple myeloma" Blood Cancer J (2013) 10.1038/bcj.2013.1

[43]

Licht "MEK and MAF in myeloma therapy" Blood (2011) 10.1182/blood-2011-01-327262

[44]

Morgan "A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial" Leukemia (2012) 10.1038/leu.2011.204

[45]

Shaughnessy "Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation" Blood (2006) 10.1182/blood-2006-03-009910

[46]

Inazawa "Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma" Am J Pathol (2004) 10.1016/s0002-9440(10)63276-2

[47]

Shaughnessy "Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma" Hematology (2005) 10.1080/10245330512331390140

[48]

Brown "Identification and partial characterization of PDZK1: a novel protein containing PDZ interaction domains" Lab Invest (1998)

[49]

Borst "Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines" Cancer Res (1997)

[50]

Shaughnessy "CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms" Blood (2007) 10.1182/blood-2006-07-038703

Showing 50 of 253 references

Metrics

139

Citations

253

References

Details

Published: Nov 24, 2013
Vol/Issue: 4(12)
Pages: 2186-2207

Authors

J

Jahangir Abdi

Division of Immunopharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands

G

Guoan Chen

Dept. of Hematology & Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China

H

Hong Chang

Division of Molecular and Cellular Biology, Toronto General Research Institute; Dept. of Laboratory Medicine & Pathobiology, University of Toronto; Dept. of Laboratory Hematology, University Health Network, Toronto, Ontario, Canada

Cite This Article

Jahangir Abdi, Guoan Chen, Hong Chang (2013). Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget, 4(12), 2186-2207. https://doi.org/10.18632/oncotarget.1497

Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms

You May Also Like